The Belgian company ElmediX has already raised almost 12 million euros to develop a heat treatment for cancer patients. The Mechelen spin-off of the University of Antwerp reports this in a press release.
The treatment involves patients experiencing a controlled heating of their body temperature to 41.5 degrees for several hours. This would increase the sensitivity of cancer cells to chemotherapy and radiotherapy, increasing the chance of successful treatment.
Especially in difficult tumors such as pancreatic cancer or metastatic cancers, the technology would have a significant impact.
With a new capital injection of 4 million euros, the company was already able to raise 12 million euros. This also includes 1.8 million euros in Flemish research grants.
The safety and efficacy of the method are currently under investigation. For its scientific research, ElmediX works together with the universities of Antwerp, Ghent, Amsterdam and Rotterdam and a research center in Genoa.
“The results in the first patients are promising,” said Professor John-Paul Bogers, CEO of ElmediX. “The confidence of our investors and the additional capital injection allows us to expand the first clinical trial and treat more patients. We are also developing a biomarker that can indicate in advance which patients and/or cancers have an increased chance of a response.”
The treatment involves patients experiencing a controlled heating of their body temperature to 41.5 degrees for several hours. This would increase the sensitivity of cancer cells to chemotherapy and radiotherapy, increasing the chance of successful treatment. The technology would have a significant impact, especially in difficult tumors such as pancreatic cancer or metastatic cancer. With a new capital injection of 4 million euros, the company was already able to raise 12 million euros. This also includes 1.8 million euros in Flemish research grants. The safety and efficacy of the method are currently under investigation. For its scientific research, ElmediX works together with the universities of Antwerp, Ghent, Amsterdam and Rotterdam and a research center in Genoa. “The results in the first patients are promising,” said Professor John-Paul Bogers, CEO of ElmediX. “The confidence of our investors and the additional capital injection allows us to expand the first clinical trial and treat more patients. We are also developing a biomarker that can indicate in advance which patients and/or cancers have an increased chance of a response.”
–
